PROCEPT BioRobotics (NASDAQ:PRCT) Given “Market Perform” Rating at Oppenheimer

Oppenheimer restated their market perform rating on shares of PROCEPT BioRobotics (NASDAQ:PRCT) in a research report report published on Thursday morning, MarketBeat reports.

A number of other analysts have also recently weighed in on the company. Piper Sandler reaffirmed an “overweight” rating and set a $50.00 price objective (down from $55.00) on shares of PROCEPT BioRobotics in a research report on Wednesday, November 5th. Truist Financial decreased their price target on PROCEPT BioRobotics from $50.00 to $47.00 and set a “buy” rating for the company in a report on Thursday, December 18th. UBS Group assumed coverage on shares of PROCEPT BioRobotics in a research report on Friday, December 12th. They issued a “buy” rating and a $62.00 price objective on the stock. Wall Street Zen upgraded shares of PROCEPT BioRobotics from a “sell” rating to a “hold” rating in a research report on Saturday, January 10th. Finally, TD Cowen reduced their target price on shares of PROCEPT BioRobotics from $85.00 to $50.00 and set a “buy” rating for the company in a research note on Wednesday, November 5th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, PROCEPT BioRobotics has a consensus rating of “Moderate Buy” and a consensus price target of $43.60.

PROCEPT BioRobotics Stock Down 15.1%

PRCT stock opened at $23.63 on Thursday. The company has a market cap of $1.32 billion, a price-to-earnings ratio of -13.82 and a beta of 0.99. The company has a fifty day moving average price of $30.18 and a 200 day moving average price of $33.64. The company has a debt-to-equity ratio of 0.14, a current ratio of 8.44 and a quick ratio of 7.20. PROCEPT BioRobotics has a 12 month low of $19.35 and a 12 month high of $68.70.

PROCEPT BioRobotics (NASDAQ:PRCT) last posted its quarterly earnings data on Wednesday, February 25th. The company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.21). PROCEPT BioRobotics had a negative net margin of 31.02% and a negative return on equity of 24.82%. The business had revenue of $76.38 million during the quarter, compared to analyst estimates of $93.70 million. During the same quarter in the prior year, the firm posted ($0.35) earnings per share. The company’s revenue for the quarter was up 11.9% compared to the same quarter last year. Sell-side analysts expect that PROCEPT BioRobotics will post -1.75 earnings per share for the current year.

Institutional Investors Weigh In On PROCEPT BioRobotics

Several institutional investors and hedge funds have recently made changes to their positions in PRCT. Mitsubishi UFJ Trust & Banking Corp acquired a new position in PROCEPT BioRobotics in the 2nd quarter valued at about $5,892,000. Lisanti Capital Growth LLC purchased a new stake in shares of PROCEPT BioRobotics during the second quarter worth about $2,532,000. Mitsubishi UFJ Asset Management Co. Ltd. raised its position in shares of PROCEPT BioRobotics by 109.3% in the second quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 159,874 shares of the company’s stock valued at $9,209,000 after buying an additional 83,498 shares during the last quarter. Chicago Capital LLC lifted its stake in shares of PROCEPT BioRobotics by 175.7% during the third quarter. Chicago Capital LLC now owns 1,568,845 shares of the company’s stock valued at $55,992,000 after buying an additional 999,873 shares during the period. Finally, Candriam S.C.A. boosted its position in PROCEPT BioRobotics by 104.8% during the second quarter. Candriam S.C.A. now owns 63,125 shares of the company’s stock worth $3,636,000 after acquiring an additional 32,301 shares during the last quarter. 89.46% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about PROCEPT BioRobotics

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Positive Sentiment: Solid cash runway and improving operating losses — Q4 showed an improved operating loss and the company ended the quarter with roughly $286.5M in cash and total liabilities of $142.2M, which supports near‑term execution. Quiver Quant Earnings Summary
• Positive Sentiment: FY‑2026 revenue guidance range ($390M–$410M) was raised/updated and sits near analyst consensus, giving some multi‑quarter visibility for modeling. Q4 Results & Guidance (GlobeNewswire)
• Neutral Sentiment: Company hosted an Investor Day outlining its multi‑year plan — strategic detail may help longer‑term sentiment but did not offset near‑term headline risk. Investor Day Release
• Negative Sentiment: Earnings and revenue misses — Q4 revenue of ~$76.4M (+11.9% YoY) and diluted loss of $0.53 missed consensus (revenue and EPS), and Q1 revenue guidance ($79M–$82M) came in well below street expectations — the primary catalyst for selling. Q4 Results & Guidance (GlobeNewswire)
• Negative Sentiment: New securities‑fraud investigation announced by law firm Ademi LLP, alleging possible inaccurate statements about financials/operations — this raises regulatory/legal overhang and investor risk. Ademi LLP Investigation
• Negative Sentiment: Multiple analyst price‑target cuts and a Bank of America downgrade to underperform (PT $20) plus cuts from Leerink, TD Cowen and Piper Sandler increased selling pressure; some firms remain constructive but consensus risk has risen. Analyst Coverage/Benzinga TD Cowen Comment
• Negative Sentiment: Heavy institutional selling and a spike in volume pushed the stock to a 52‑week low; hedge‑fund and mutual‑fund position reductions magnified the decline. Quiver Quant (institutional moves) Benzinga: 52‑Week Low

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.